- Recruiting
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM
Updated: May 25, 2022
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Sponsor
Multiple Locations
International Study
Official Title: A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma
First Posted : May 10, 2021
Click here for details on ClinicalTrials.gov
Drug: HDP-101
Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101 (Code C179409)
ADC HDP-101
Anti-BCMA Antibody-drug Conjugate HDP-101
Anti-BCMA/Alpha-amanitin ADC HDP-101
Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101
HDP 101
HDP-101
HDP101
Locations
United States, Georgia
United States, New York
United States, Texas
Europe
Germany